This study reveals CD112-mediated immune checkpoint axis dysregulation in monosomy 7-associated myeloid neoplasms, providing direct evidence for developing immunotherapeutic strategies targeting TIGIT and PVRIG, and inspiring precision intervention approaches for high-risk cytogenetic abnormalities.
Literature Overview
This article, 'A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms,' published in Signal Transduction and Targeted Therapy, systematically investigates the molecular and immunological mechanisms of monosomy 7 (−7) in myeloid neoplasms. By integrating transcriptomic and methylomic analyses, the study identifies a unique stem cell program and aberrant CD112 expression driven by IKZF1 loss, and for the first time defines the functional impairment of the TIGIT-PVRIG-DNAM1/CD112 axis. These findings provide new insights into the poor prognosis associated with −7 and suggest potential targetable mechanisms.Background Knowledge
Myeloid neoplasms (MN) are a heterogeneous group of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), characterized by rapid clinical progression and limited treatment options. Monosomy 7 (−7), a common chromosomal deletion occurring in 10–20% of MN patients, is frequently associated with complex karyotypes and is a well-established high-risk prognostic marker. Although previous studies have implicated genes on chromosome 7—such as SAMD9/SAMD9L and EZH2—in disease pathogenesis, the comprehensive molecular mechanisms underlying −7 remain poorly understood, particularly with regard to effective targeted therapies. Recently, CD112 has gained attention for its role in tumor immune escape, acting as a ligand for TIGIT and PVRIG to promote immune tolerance by inhibiting NK and T cell functions. However, the regulatory mechanisms of CD112 in MN and its relationship with −7 have not been systematically elucidated. This study addresses these gaps by integrating epitranscriptomic approaches to comprehensively analyze the stem cell programs and immune checkpoint networks associated with −7, aiming to identify actionable pathogenic axes and bridge the mechanistic and translational divide in this field.
Research Methods and Experiments
The research team performed RNA-seq and mERRBS to analyze transcriptomic and methylomic profiles in MDS/AML patients with −7, MN patients with normal karyotypes, and healthy controls. CIBERSORTx was used for cell deconvolution to reduce heterogeneity in bone marrow samples. Key findings were validated using public datasets (TCGA LAML, Beat AML). To investigate IKZF1 regulation of CD112, the authors integrated qRT-PCR, ChIP-seq, and CUT&RUN experiments to confirm binding, and validated CD112 expression changes by CRISPR-Cas9 knockdown of IKZF1 in normal CD34+ progenitor cells. Additionally, immunohistochemistry and flow cytometry were used to analyze CD112 protein expression and the distribution of its receptors—TIGIT, PVRIG, and DNAM1—on NK and CD3+ cells. Finally, an 'ex vivo' co-culture system was established, using autologous NK cells and −7-bearing leukemia cells in cytotoxicity assays to evaluate the impact of blocking TIGIT and PVRIG on killing activity.Key Conclusions and Perspectives
Research Significance and Prospects
This study establishes the first direct link between chromosomal abnormalities (−7) and dysfunction of a specific immune checkpoint axis, offering new therapeutic targets for high-risk MN patients. From a drug development standpoint, dual blockade of TIGIT and PVRIG may represent an effective strategy to overcome immune escape in −7-associated disease, particularly in refractory AML/MDS patients. Furthermore, CD112 expression could serve as a biomarker for patient stratification and response prediction, enhancing the precision of clinical monitoring. The study also highlights the role of epigenetic modifications (e.g., enhancer hypermethylation) in regulating key immune molecules, supporting exploration of combination therapies involving hypomethylating agents and immune checkpoint blockade, thereby accelerating clinical translation.
Conclusion
This study systematically dissects the pathogenic mechanisms of monosomy 7-associated myeloid neoplasms at molecular, epigenetic, and immunological levels, revealing that IKZF1 loss drives CD112 overexpression and subsequent dysfunction of the TIGIT-PVRIG-DNAM1 signaling axis, forming a core pathway of immune escape. This discovery not only deepens our understanding of the poor prognosis associated with −7 but also identifies actionable immune intervention nodes. From bench to bedside, this work lays a mechanistic foundation for developing precision immunotherapies targeting high-risk cytogenetic abnormalities. In the future, patient stratification based on CD112 expression status combined with dual TIGIT/PVRIG blockade may improve survival outcomes in these refractory patients. Moreover, this study emphasizes the importance of integrating multi-omics analyses in myeloid neoplasms to uncover functional immune regulatory mechanisms, offering a new paradigm for building more clinically relevant disease models and efficacy evaluation systems, potentially advancing the entire care framework toward greater precision and personalization.
